Wolny-Rokicka Edyta, Wydmański Jerzy, Tukiendorf Andrzej, Mróz Piotr, Gramacka Katarzyna, Namysł-Kaletka Agnieszka, Lipiński Jakub, Zembroń-Łacny Agnieszka
Radiotherapy Development Department in Provincial Multidisciplinary Hospital in Gorzów Wielkopolski, ul Dekerta 1, 66-400 Gorzow Wielkopolski LLC, Poland.
University of Zielona Góra, Faculty of Medicine and Health Sciences, ul. Zyty 28, 65-046 Zielona Góra, Poland. Email:
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):53-57. doi: 10.31557/APJCP.2019.20.1.53.
Purpose: This study aimed to evaluate the impact of tumor volume on platelet counts (PLT) and mean platelet volume (MPV) and involve these parameters on overall survival. Methods: It is a retrospective study of 99 patients with lung cancer (confirmed histologically or cytologically). Sixty-six patients underwent radical operating treatment and 33 patients had only biopsies – due to the inoperable status of tumor According to the histopathology profile: non-small cell carcinoma – 23%, adenocarcinoma - 23 %, squamous - 36%, small cell carcinoma -11%, carcinoid – 6%. The overall survival was measured from the time of surgery to last observation or death. The tumor’s size was established based on information from histopathology protocol by using model for the ellipsoid (V=4/3 π r abc). Results: KM median survival time after surgery was 20 months (95% C.I. = 16–42). The survival time depends significantly on: Tumor feature, MPV (p=0.03, p=0.04). Patients with normal PLT levels have longer survival time (median: 11 months) than thrombocytosis group (9.5) (p=0.6). Following both the PLT and MPV, a change-point that is equal to approximately 18.5 cm3 (approx. 3.3 cm in diameter) stands for a segmented relationship between tumor volume and analyzed blood indicators. Conclusions: After an overstepping of the change-point of tumor volume inflammatory processes start and they are associated with poor prognosis. MPV may be a valuable biomarker for the diagnosis and follow up of various types of carcinoma.
本研究旨在评估肿瘤体积对血小板计数(PLT)和平均血小板体积(MPV)的影响,并探讨这些参数对总生存期的影响。方法:这是一项对99例肺癌患者(经组织学或细胞学确诊)的回顾性研究。66例患者接受了根治性手术治疗,33例患者仅进行了活检——由于肿瘤无法手术切除。根据组织病理学特征:非小细胞癌——23%,腺癌——23%,鳞状细胞癌——36%,小细胞癌——11%,类癌——6%。总生存期从手术时间至最后一次观察或死亡进行测量。肿瘤大小根据组织病理学记录中的信息,使用椭球体模型(V = 4/3πrabc)确定。结果:术后KM中位生存期为20个月(95%置信区间= 16 - 42)。生存时间显著取决于:肿瘤特征、MPV(p = 0.03,p = 0.04)。血小板水平正常的患者生存期更长(中位值:11个月),高于血小板增多组(9.5个月)(p = 0.6)。在血小板计数和平均血小板体积方面,一个约为18.5立方厘米(直径约3.3厘米)的变化点代表肿瘤体积与分析的血液指标之间的分段关系。结论:肿瘤体积超过变化点后,炎症过程开始,且与预后不良相关。平均血小板体积可能是各类癌症诊断和随访的有价值生物标志物。